Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by collaborator Qilu Pharmaceutical Co., Ltd. The investigational siRNA drug targets PCSK9, an enzyme closely associated with controlling low-density lipoprotein (LDL) cholesterol levels.

In December 2023, exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau were granted to Qilu Pharmaceutical. The product may not ultimately achieve successful development or commercialization, so shareholders and potential investors are advised to exercise caution when dealing in the shares of Suzhou Ribo Life Science Co., Ltd. (6938).